GLP-1 Agonists and the
Immune System

GLP-1 Receptors on Immune Cells: A Molecular Footprint

For most of its clinical history, GLP-1 (glucagon-like peptide 1) was understood as an incretin hormone — a signal released from intestinal L-cells after eating that prompts the pancreas to release insulin. That story is incomplete. The GLP-1 receptor (GLP-1R) is expressed far beyond the pancreas, and some of the most consequential sites are immune cells.

Where GLP-1 receptors are found in the immune system

Robust expression of GLP-1R has been identified on:

• Macrophages — both tissue-resident macrophages and monocyte-derived macrophages express GLP-1R. This is where the most-studied anti-inflammatory action occurs.
• Dendritic cells — GLP-1 signaling in dendritic cells appears to shift antigen presentation toward tolerogenic rather than inflammatory phenotypes, influencing downstream T-cell activation.
• T lymphocytes — GLP-1R is detectable on CD4+ T-cells, and activation of this receptor modulates regulatory T-cell (Treg) differentiation, promoting immune tolerance over attack.
• Neutrophils — GLP-1R activation in neutrophils reduces oxidative burst activity and diminishes the production of reactive oxygen species, contributing to reduced tissue damage in inflammatory states.
• Microglia — the brain's resident immune cells express GLP-1R, a discovery with significant implications for neuroinflammatory conditions (see Section 5).

This distribution means GLP-1 receptor agonists like semaglutide, liraglutide, and tirzepatide deliver anti-inflammatory signals not merely as a side effect of weight loss, but through direct receptor-mediated signaling in immune tissue.

How GLP-1 Agonists Suppress Inflammation at the Cellular Level

The anti-inflammatory actions of GLP-1 receptor agonists converge on several well-characterized molecular pathways. Understanding them clarifies why the clinical effects are so broad.

NF-κB inhibition: the master switch

Nuclear factor kappa B (NF-κB) is the master transcription factor governing inflammatory gene expression. When activated — by infections, oxidized lipids, cytokines, or hyperglycemia — NF-κB drives the production of TNF-α, IL-6, IL-1β, MCP-1, and dozens of other pro-inflammatory mediators. GLP-1 receptor activation raises intracellular cAMP, which activates PKA, which in turn phosphorylates and stabilizes the inhibitory protein IκB. Stabilized IκB keeps NF-κB sequestered in the cytoplasm rather than translocating to the nucleus. The result is a blunted transcriptional output of the entire inflammatory cascade.

Cytokine profile changes

Across human clinical trials and animal models, GLP-1 receptor agonist treatment consistently shifts the cytokine milieu in an anti-inflammatory direction:

• IL-6 ↓ — reduced in multiple RCTs; IL-6 drives acute-phase protein production including CRP and fibrinogen.
• IL-1β ↓ — the NLRP3 inflammasome pathway (which generates IL-1β) is suppressed by GLP-1R signaling in macrophages.
• TNF-α ↓ — reduced in adipose tissue particularly, where macrophage infiltration drives systemic TNF-α output in obesity.
• CRP / hsCRP ↓ — a downstream readout of IL-6 signaling; reduced 37% in the SELECT trial, 13% in the SUSTAIN-6 trial, and consistently in liraglutide studies.
• Adiponectin ↑ — the anti-inflammatory adipokine is increased, while leptin (a pro-inflammatory adipokine in obesity) falls with fat mass reduction.

Macrophage polarization: M1 → M2 shift

Macrophages exist on a functional spectrum. The M1 phenotype is classically activated — it kills pathogens, produces IL-12, TNF-α, and nitric oxide, and drives tissue destruction in excess. The M2 phenotype is alternatively activated — it resolves inflammation, promotes tissue repair, and produces IL-10 and TGF-β. In obese adipose tissue, the balance tips dramatically toward M1. GLP-1 receptor agonists shift this balance back toward M2 polarization through both direct GLP-1R signaling on macrophages and indirect effects mediated by reduced adipocyte lipotoxicity and lower local free fatty acid concentrations.

Adipose tissue immune remodeling

Visceral adipose tissue in obesity is not inert fat storage — it is an inflamed organ. Crown-like structures (CLS), which are rings of M1 macrophages surrounding dying adipocytes, are a histological hallmark of inflammatory adipose tissue. Studies using semaglutide and liraglutide in rodents and humans demonstrate marked reductions in CLS density, macrophage infiltration, and local cytokine concentrations. Adiponectin — which has insulin-sensitizing and anti-inflammatory properties — rises substantially as fat mass falls and local inflammation resolves.

The SELECT Trial: Cardiovascular Protection Beyond Weight Loss

The Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) trial, published in the New England Journal of Medicine in 2023, represents one of the most consequential trial results in the history of GLP-1 medicine — and one of the clearest demonstrations that its benefits are not solely metabolic.

Trial design and population

SELECT enrolled 17,604 adults aged 45 or older with overweight or obesity (BMI ≥ 27) and established cardiovascular disease, but without diabetes. This non-diabetic population is the crucial differentiator: previous cardiovascular outcomes trials (LEADER, SUSTAIN-6, PIONEER 6) enrolled patients with type 2 diabetes, where glycemic improvement could explain much of the benefit. SELECT removed that confound.

Primary and inflammatory outcomes

Participants received weekly subcutaneous semaglutide 2.4 mg or placebo over a median of 34 months. Key findings:

• Major adverse cardiovascular events (MACE — cardiovascular death, non-fatal MI, non-fatal stroke) were reduced by 20% in the semaglutide arm (HR 0.80, 95% CI 0.72–0.90, p<0.001).
• High-sensitivity CRP (hsCRP) — the most widely used clinical marker of systemic inflammation — fell by 37% more in the semaglutide group than in the placebo group.
• The cardiovascular benefit appeared early in the trial, within months, and before the majority of weight loss had accrued — a pattern more consistent with direct anti-inflammatory and plaque-stabilizing effects than with metabolic improvement.
• Subgroup analyses showed consistent benefit regardless of baseline body weight, suggesting a weight-independent mechanism at least partially responsible for cardiovascular protection.

What this means for patients with inflammatory cardiovascular risk

The SELECT results reshape how clinicians and patients should think about GLP-1 agonists. For someone with elevated hsCRP, metabolic syndrome, or a history of cardiovascular events, the anti-inflammatory case for semaglutide is now supported by Level 1 evidence — a randomized, double-blind, placebo-controlled trial with hard cardiovascular endpoints in a population that could not have benefited from glucose lowering.

GLP-1 Agonists Across Inflammatory Conditions: Evidence Grades

Specific Inflammatory Conditions: What the Data Shows

NASH and liver inflammation

Non-alcoholic steatohepatitis (NASH), now increasingly called metabolic dysfunction-associated steatohepatitis (MASH), is characterized by hepatic fat accumulation plus active inflammatory injury — lobular inflammation, hepatocyte ballooning, and progressive fibrosis. The Phase 2 NASH trial of semaglutide (0.4 mg daily subcutaneous) showed 59% of participants in the highest-dose arm achieved NASH resolution without worsening of fibrosis, compared to 17% on placebo. A Phase 3 trial (ESSENCE) is underway. The mechanism appears to be a combination of reduced hepatic lipotoxicity, direct GLP-1R signaling in hepatic Kupffer cells (liver macrophages), and systemic reduction in adipose-derived inflammatory mediators reaching the liver via the portal circulation.

Chronic kidney disease

Renal inflammation drives progressive CKD. The FLOW trial — the first dedicated renal outcomes trial for a GLP-1 receptor agonist — randomized 3,533 patients with type 2 diabetes and CKD to semaglutide 1.0 mg or placebo. The trial was stopped early due to overwhelming efficacy: a 24% reduction in the composite kidney endpoint (sustained eGFR decline ≥50%, kidney failure, or renal/cardiovascular death). The renal protective effects likely reflect both hemodynamic improvements and anti-inflammatory attenuation of glomerular and tubulointerstitial inflammation.

Psoriasis

Psoriasis is a systemic immune-mediated inflammatory disease driven by dysregulated Th17 and Th1 T-cell activity. It is disproportionately prevalent in patients with obesity and metabolic syndrome, and adipose-derived cytokines appear to be a driver of disease severity. Several case series have described marked improvement in Psoriasis Area and Severity Index (PASI) scores in patients initiated on semaglutide. Subgroup analyses from SELECT also noted reduced rates of new or worsening inflammatory skin conditions in the semaglutide arm. These are not approval-level data, but the signal is consistent with the mechanistic hypothesis.

Rheumatoid arthritis

Rheumatoid arthritis (RA) is characterized by synovial macrophage activation and elevated TNF-α, IL-6, and IL-1β — the same cytokines GLP-1 agonists suppress. Small observational studies in RA patients who started semaglutide for weight management have reported reductions in CRP and patient-reported pain scores. The GLORIA trial and related investigations are formally evaluating GLP-1 agonists in RA, but results are not yet available. For now, this remains a promising but unvalidated indication.

COVID-19 outcomes

The COVID-19 pandemic brought renewed attention to the intersection of obesity, inflammation, and infectious disease severity. Obesity is a major independent risk factor for severe COVID-19, ICU admission, and death — mediated in part through baseline hyperinflammation, impaired innate immune responses, and reduced lung reserve. Multiple retrospective analyses and database studies found that patients taking GLP-1 receptor agonists prior to COVID-19 infection had lower rates of hospitalization, ICU admission, and mortality compared to patients with similar BMI and comorbidities not on GLP-1 therapy. Confounding in observational data is a genuine concern, but the direction of effect is consistent across studies.

Neuroinflammation, Gut Immunity, and the Peripheral–Central Divide

Microglial modulation and neuroinflammation

Microglia are the brain's resident macrophages, comprising approximately 10–15% of all cells in the central nervous system. In conditions like Alzheimer's disease and Parkinson's disease, chronically activated microglia — analogous to M1 macrophages in the periphery — drive neuronal injury through sustained production of TNF-α, IL-1β, and reactive oxygen species. The GLP-1 receptor is expressed on microglia, and rodent studies show that liraglutide and semaglutide shift microglia toward a less activated, more surveilling phenotype while reducing amyloid burden and improving dopaminergic neuron survival respectively.

Human data remain preliminary. The ELAD trial (liraglutide in early Alzheimer's) and the ongoing Exenatide-PD trial have generated mixed but intriguing signals. Semaglutide is currently being evaluated in two large Phase 3 trials in early Alzheimer's disease (EVOKE and EVOKE Plus), with results anticipated by 2025–2027. If these trials are positive, GLP-1 agonists will represent the first systemic anti-inflammatory approach to neurodegeneration with broad clinical access.

Gut immunity: L-cells and lymphoid tissue

GLP-1 is not an exogenous drug in the body — it is a native hormone produced by L-cells in the distal small intestine and colon. These L-cells are anatomically integrated into the gut-associated lymphoid tissue (GALT), the largest immune organ in the body by mass. They sit adjacent to Peyer's patches, mesenteric lymph nodes, and intraepithelial lymphocytes. GLP-1 signaling may function as part of a nutritional immune checkpoint — a signal that tells the gut immune system that the host is fed and safe, modulating mucosal cytokine tone accordingly.

GLP-1 receptor agonists delivered systemically appear to amplify this signal, promoting regulatory T-cell activity in gut lymphoid tissue and reducing mucosal IL-17 and IFN-γ in animal models. Whether this translates to meaningful clinical benefit in conditions like Crohn's disease or ulcerative colitis remains to be established. Importantly, confusion with GLP-2 (a structurally related peptide co-secreted by L-cells) has generated unnecessary concern about GLP-1 agonists and IBD — see the warnings section below.

Peripheral versus central immune effects

A meaningful distinction exists between how GLP-1 agonists affect peripheral immune cells (macrophages in adipose tissue, liver, kidney, joints) versus central immune cells (microglia). Peripheral effects are more established — the clinical trial data on CRP reduction, macrophage polarization, and visceral adipose inflammation is robust. Central effects require GLP-1 agonists to cross or signal through the blood-brain barrier, which most current molecules do partially but not completely. Next-generation CNS-penetrant GLP-1 agonists are in development specifically to maximize neuroinflammatory benefits.